| Similar Articles |
|---|
 |
The Motley Fool
December 6, 2011
Travis Hoium |
Protalix BioTherapeutics Shares Got Crushed: What You Need to Know Is this meaningful or just another movement for Protalix BioTherapeutics?   |
The Motley Fool
December 1, 2009
Brian Orelli |
Pfizer Takes In an Orphan on the Cheap Steal is a pretty accurate term for the price Pfizer paid for Protalix BioTherapeutics' taliglucerase alfa. |
The Motley Fool
December 7, 2011
Brian Orelli |
As the Biotech Saying Goes... Another delay for Protalix BioTherapeutics makes you think. |
The Motley Fool
February 3, 2010
Brian Orelli |
Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease. |
The Motley Fool
February 25, 2011
Brian Orelli |
Minor Delay, Major Missed Opportunity Protalix and Pfizer's Gaucher disease drug gets delayed. |
The Motley Fool
September 2, 2010
Brian Orelli |
Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases. |
The Motley Fool
February 17, 2010
Brian Orelli |
Execute Well or You're Out Genzyme needs to show investors that it can rebuild. |
The Motley Fool
December 29, 2011
Brian Orelli |
Too Early for a New Biotech Orphan? Alexion Pharmaceuticals is profitable with a drug on the market. The next logical step in the progression of a biotech is to buy another company to stock the pipeline. |
Car and Driver
December 2006
Ray Hutton |
2009 Alfa Romeo 8C Competizione Once a tease, always a tease. Alfa says this $200,000 knockout will lead its return to America. Just don't ask when. |
